RN / Board Member
Paula´s skillset spans global commercialization planning, pre-launch preparation, major launch initiatives for first-in-class agents, and patient advocacy. She has been involved in introducing and supporting brands like Imbruvica (ibrutinib), Glivec/Gleevec (imatinib), Aranesp (darbopoetin), Camptosar (irinotecan), and Vectibix (panitumumab). In addition, Paula has held top-tier positions, as well as consulted, for major companies including Pharmacia (Pfizer), Novartis, Amgen, Proteolix (Onyx), Dendreon, Incyte, and Pharmacyclics, among others. Most recently Paula was Chief Commercial Officer at Oncopeptides AB. Currently she is board chair at the Max Foundation.
Position: Board Member
Year of birth: 1958
Holdings: 0 shares*
Independent in relation to the company and its management: Yes
Independent in relation to larger shareholders: Yes
*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of September 30, 2022.